Doxofylline Dosing in Adults
The recommended dose of doxofylline for adults with COPD, asthma, or bronchospasm is 400 mg three times daily (1200 mg total daily dose). 1, 2, 3
Standard Dosing Regimen
For chronic obstructive pulmonary disease and asthma, administer doxofylline 400 mg orally three times daily. This dosing has been validated in multiple clinical trials and demonstrates optimal bronchodilator efficacy with acceptable tolerability 1, 2, 3.
Key Dosing Details:
- Standard adult dose: 400 mg three times daily (TID)
- Total daily dose: 1200 mg
- Route: Oral administration
- Duration: Can be used for chronic maintenance therapy (studied up to 12 weeks in clinical trials) 2
Evidence Supporting This Dose
The 400 mg TID regimen has been specifically studied and shown to:
- Significantly improve spirometric parameters (FEV1, FVC, FEF25-75%) compared to placebo 2
- Reduce asthma attack rates and rescue bronchodilator use 2
- Achieve therapeutic serum levels of 12-15 mcg/mL, which correlates with bronchodilator efficacy 3
- Demonstrate superior tolerability compared to theophylline at equivalent bronchodilator doses 1, 2
Lower Dose Consideration
A 200 mg TID dose (600 mg total daily) has been studied but showed minimal differences from placebo in clinical trials 2. This lower dose is not recommended for achieving meaningful bronchodilation in adults with moderate to severe airway obstruction.
Clinical Context and Positioning
Doxofylline should be considered as add-on therapy in patients with COPD or asthma who remain symptomatic despite standard bronchodilator therapy. While established COPD guidelines 4, 5, 6 recommend inhaled bronchodilators (beta-agonists and anticholinergics) as first-line therapy, methylxanthines like doxofylline can be tried in patients with severe disease who need additional bronchodilation, particularly when they demonstrate responsiveness to beta-agonists 4.
When to Use Doxofylline:
- Patients with moderate to severe COPD (FEV1 <60% predicted) inadequately controlled on inhaled bronchodilators 1, 3
- Patients with chronic reversible asthma requiring additional controller therapy 2
- Particularly effective in patients who show acute response to inhaled beta-2 agonists (>20% FEV1 improvement) 3
Safety and Monitoring
Doxofylline demonstrates significantly better tolerability than theophylline, with fewer adverse events and lower dropout rates 1, 2. In comparative trials:
- Adverse event rate: 8 events with doxofylline vs. 25 with theophylline 1
- Treatment discontinuation: 5 patients on doxofylline vs. 10 on theophylline 1
- Number needed to treat to spare one dropout: 5 patients 2
Important Safety Points:
- No routine serum level monitoring required (unlike theophylline) 1, 2
- Common side effects include dyspepsia, nausea, and anxiety, but occur less frequently than with theophylline 3
- Therapeutic serum range appears to be 12-15 mcg/mL based on pharmacokinetic studies 3
- Elimination half-life is approximately 7 hours after oral administration 7
Critical Caveats
Do not confuse doxofylline with doxepin - the FDA drug label information provided 8 refers to doxepin (a tricyclic antidepressant used for insomnia at 3-6 mg doses), which is an entirely different medication with no role in respiratory disease.
Doxofylline is not available in all markets - it is primarily used in Europe, Asia, and some other regions but is not FDA-approved in the United States. The evidence base, while positive, consists primarily of smaller trials rather than large-scale international studies 1, 2, 3.